Citrate phosphate dextrose (CPD) anticoagulant in blood transfusion

J. McCullough, B. J. Weiblen

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Compared to ACD anticoagulant, CPD has the following advantages for blood preservation: (1) isotonicity for red blood cells, thus minimizing the lesion of collection and resulting in improved red blood cell survival, (2) more physiological pH, (3) 15% less citrate ion, and (4) improved red cell oxygen transport. Many blood banks are now beginning the routine use of CPD in blood collections. This should result in an improved blood product for patient therapy.

Original languageEnglish (US)
Pages (from-to)980-982
Number of pages3
JournalMinnesota Medicine
Volume56
Issue number11
StatePublished - Dec 1 1973

Fingerprint

Blood Transfusion
Anticoagulants
Erythrocytes
Blood Preservation
Blood Banks
Citric Acid
Cell Survival
Ions
Oxygen
citrate phosphate dextrose
Therapeutics

Cite this

McCullough, J., & Weiblen, B. J. (1973). Citrate phosphate dextrose (CPD) anticoagulant in blood transfusion. Minnesota Medicine, 56(11), 980-982.

Citrate phosphate dextrose (CPD) anticoagulant in blood transfusion. / McCullough, J.; Weiblen, B. J.

In: Minnesota Medicine, Vol. 56, No. 11, 01.12.1973, p. 980-982.

Research output: Contribution to journalArticle

McCullough, J & Weiblen, BJ 1973, 'Citrate phosphate dextrose (CPD) anticoagulant in blood transfusion', Minnesota Medicine, vol. 56, no. 11, pp. 980-982.
McCullough, J. ; Weiblen, B. J. / Citrate phosphate dextrose (CPD) anticoagulant in blood transfusion. In: Minnesota Medicine. 1973 ; Vol. 56, No. 11. pp. 980-982.
@article{dfc20a9cce5b43e9b1df1cd9894beffb,
title = "Citrate phosphate dextrose (CPD) anticoagulant in blood transfusion",
abstract = "Compared to ACD anticoagulant, CPD has the following advantages for blood preservation: (1) isotonicity for red blood cells, thus minimizing the lesion of collection and resulting in improved red blood cell survival, (2) more physiological pH, (3) 15{\%} less citrate ion, and (4) improved red cell oxygen transport. Many blood banks are now beginning the routine use of CPD in blood collections. This should result in an improved blood product for patient therapy.",
author = "J. McCullough and Weiblen, {B. J.}",
year = "1973",
month = "12",
day = "1",
language = "English (US)",
volume = "56",
pages = "980--982",
journal = "Minnesota Medicine",
issn = "0026-556X",
publisher = "Minnesota Medical Association",
number = "11",

}

TY - JOUR

T1 - Citrate phosphate dextrose (CPD) anticoagulant in blood transfusion

AU - McCullough, J.

AU - Weiblen, B. J.

PY - 1973/12/1

Y1 - 1973/12/1

N2 - Compared to ACD anticoagulant, CPD has the following advantages for blood preservation: (1) isotonicity for red blood cells, thus minimizing the lesion of collection and resulting in improved red blood cell survival, (2) more physiological pH, (3) 15% less citrate ion, and (4) improved red cell oxygen transport. Many blood banks are now beginning the routine use of CPD in blood collections. This should result in an improved blood product for patient therapy.

AB - Compared to ACD anticoagulant, CPD has the following advantages for blood preservation: (1) isotonicity for red blood cells, thus minimizing the lesion of collection and resulting in improved red blood cell survival, (2) more physiological pH, (3) 15% less citrate ion, and (4) improved red cell oxygen transport. Many blood banks are now beginning the routine use of CPD in blood collections. This should result in an improved blood product for patient therapy.

UR - http://www.scopus.com/inward/record.url?scp=0015844379&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0015844379&partnerID=8YFLogxK

M3 - Article

VL - 56

SP - 980

EP - 982

JO - Minnesota Medicine

JF - Minnesota Medicine

SN - 0026-556X

IS - 11

ER -